Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients. We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in surveillance to assess the lead time of postoperative tumor relapse in stage ⅢA NSCLC patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
Study Type
OBSERVATIONAL
Enrollment
145
Peking University People's Hospital
Beijing, Beijing Municipality, China
Guang Dong General Hospital, Thoracic Surgery
Guangzhou, Guangdong, China
Jiang Su Cancer Hospital
Nanjing, Jiangsu, China
Lead time of tumor relapse detection by blood or urine circulation tumor DNA than radiographic approaches
Time frame: 4 years
Lead time of tumor relapse detection by blood or urine circulation tumor DNA than tumor markers
Time frame: 4 years
The concordance of ctDNA genomic alterations detection in peripheral blood and urine with those in matched tumor sample
Time frame: 1 year
Correlation of blood and urine ctDNA concentration before surgery with clinical features and prognosis
Time frame: 4 years
Correlation of blood and urine ctDNA concentration 3 days after surgery with clinical features and prognosis
Time frame: 4 years
CtDNA predictive value between locoregional recurrence and distant metastasis
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.